Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Core Viewpoint - Tenax Therapeutics, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its focus on developing novel cardiopulmonary therapies [1]. Company Overview - Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company specializing in cardiopulmonary therapies [3]. - The company holds global rights to develop and commercialize levosimendan, targeting PH-HFpEF, the most common form of pulmonary hypertension, for which no product has been approved to date [3]. - Tenax Therapeutics is publicly traded on The Nasdaq Stock Market under the symbol "TENX" [3]. Event Details - The fireside chat will feature Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer [2]. - The event is scheduled for February 11, 2026, at 12:30 p.m. ET [2]. - A live and archived webcast of the presentation will be available on the company's investor relations webpage [2].